Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: Biochemical and pharmacological implications

Biochemical and Biophysical Research Communications

Volumn 319, Issue 3, 2004, Pages 967-973

  Scatena, Roberto ^a   Bottoni, Patrizia ^a   Martorana, Giuseppe Ettore ^a   Ferrari, Franco ^a   De Sole, Pasquale ^a   Rossi, Cristina ^a   Giardina, Bruno ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cell differentiation; Diabetes; Fibrates; Hyperlipoproteinemias; Liver failure; Metabolic syndrome; Mitochondria; Peroxisome proliferators; Respiratory chain dysfunction; Thiazolidinediones

Indexed keywords

FATTY ACID; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE;

ANAEROBIC GLYCOLYSIS; ARTICLE; BINDING ASSAY; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOPATHOLOGY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERLIPOPROTEINEMIA; LEUKEMIA CELL; LIVER FAILURE; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECEPTOR BINDING; RESPIRATORY CHAIN; TOXICOKINETICS;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CELL DIFFERENTIATION; CELL DIVISION; CLOFIBRIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT; GEMFIBROZIL; HL-60 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MITOCHONDRIA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 2942592344     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.05.072     Document Type: Article

References (25)

1. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-147
2. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20:1999;649-688
3. Hihi A.K., Michalik L., Whali W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell. Mol. Life Sci. 59:2002;790-798
4. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health disease. Nature. 405:2000;421-424
5. Lazar M.A. Progress in cardiovascular biology: PPAR for the course. Nat. Med. 7:2001;23-24
6. Gale E.A. Lessons from the glitazones: a story of drug development. Lancet. 357:2001;1870-1875
7. Scheen A.J. Thiazolidinediones and liver toxicity. Diabetes Metab. 27:2001;305-313
8. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann. Pharmacother. 35:2001;908-917
9. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128:2002;159-168
10. Omar M.A., Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36:2002;288-295
11. Szewczyk A., Wojtczak L. Mitochondria as a pharmacological target. Pharmacol. Rev. 54:2002;101-127
12. O'Donnel V.B., Spycher S., Azzi A. Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-alpha-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain. Biochem. J. 310:1995;133-141
13. Robinson J.B. Jr., Brent L.G., Sumegi B., Srere P.A. An enzymatic approach to the study of the Krebs tricarboxylic acid cycle. Barley-Usmar B.M., Rickwood D., Wilson M.T. Mitochondria. A Practical Approach. 1987;160-161 IRL, Oxford, UK
14. Scatena R., Bottoni P., Vincenzoni F., Messana I., Martorana G.E., Nocca G., De Sole P., Maggiano N., Castagnola M., Giardina B. Bezafibrate induces a mitochondrial derangement in human cell lines. Intriguing effects for a peroxisome proliferator. Chem. Res. Toxicol. 16:2003;1440-1447
15. De Baetselier P., Scrham E. Luminescent bioassay based on macrophage cell lines. Methods Enzymol. 133:1986;507-530
16. Mahley R.W., Bersot T. Drugs used in the treatment of hyperlipoproteinemias. Hardman J.G., Limbird L.E., Goodman Gilmann A. The Pharmacological Basis of Therapeutics. 10th ed. 2001;971-1002 McGraw-Hill, New York
17. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., Holden S.A., Chen L.B., Singer S., Fletcher C., Spiegelman B.M. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 4:1998;1046-1052
18. Scatena R., Nocca G., De Sole P., Rumi C., Puggioni P., Remiddi F., Bottoni P., Ficarra S., Giardina B. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ. 6:1999;781-787
19. Crabtree B., Souter M.J., Anderson S.E. Evidence that the production of acetate in rat hepatocytes is a predominantly cytoplasmic process. Biochem. J. 257:1989;673-678
20. Leighton F., Bergseth S., Rortveit T., Christiansen E.N., Bremer J. Free acetate production by rat hepatocytes during peroxisomal fatty acid and dicarboxylic acid oxidation. J. Biol. Chem. 264:1989;10347-10350
21. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., Thomazy V.A., Evans R.M. Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat. Med. 4:1998;1058-1061
22. Lefebvre A.M., Chen I., Desreumaux P., Najib J., Fruchart J.C., Geboes K., Briggs M., Heyman R., Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4:1998;1053-1057
23. Ellis C.J., Scott R. Statins and coenzyme Q10. Lancet. 361:2003;1134-1135
24. Petersen K.F., Befroy D., Dufour S., Dziura J., Ariyan C., Rothman D.L., Di Pietro L., Cline G.W., Shulman G.I. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 300:2003;1140-1142
25. Petersen K.F., Dufour S., Befroy D., Garcia R., Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350:2004;664-671